



Blood clot

Cardiovascular & Metabolism

Led by Peter M. DiBattiste, M.D., the Cardiovascular and Metabolism Therapeutic Area (CVMTA) is committed to making a difference for the millions living with diabetes and cardiovascular disease. Cardiovascular disease is the world's leading cause of death and diabetes is a global epidemic resulting in the death of a person every eight seconds. The significant medical need in these disease areas drives the CVMTA to continue to harness our internal expertise with a focus on pursuing novel science and seizing commercial opportunities in type 2 diabetes, thrombosis and heart failure.



Peter M. DiBattiste, M.D.

Global Therapeutic Area Head, Cardiovascular & Metabolism

Dr. Peter M. DiBattiste was appointed Global Therapeutic Area Head, Cardiovascular & Metabolism, Janssen Research & Development in June 2011.

Previously, Dr. DiBattiste served as Vice President, Development Head, Cardiovascular & Urology. He joined the Johnson & Johnson family of companies in 2005 as Vice President, Cardiology.

Prior to joining Johnson & Johnson family of companies, Pete held the position of Executive Director, Cardiovascular Clinical Research at AstraZeneca, overseeing the US arm of the company's broad portfolio of projects in the areas of diabetes, thrombosis, heart failure, hypertension and dyslipidemia. He also spent six years at Merck in both Medical Affairs and Cardiovascular R&D. Before joining Merck, Pete practiced medicine for 10 years as an interventional cardiologist.

Dr. DiBattiste earned his M.D. at Harvard Medical School. Completed a residency in Internal Medicine at the University of Texas Southwestern (Parkland) and a fellowship in Cardiovascular Diseases at the University of Pennsylvania.